ORPOF (OSE Immunotherapeutics) Other Operating Expense: $-0.37 Mil (TTM As of Dec. 2025)


ORPOF OSE Immunotherapeutics SA ORPOF
51 GF Score
Price $4.43
GF Value $3.33
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Other Operating Expense?

OSE Immunotherapeutics ORPOF 51 Other Operating Expense is $-0.37 Mil as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 51/100 and a GF Value™ of $3.33 (Significantly Overvalued). The stock has 6 warning signs investors should review.

OSE Immunotherapeutics's Other Operating Expense for the six months ended in Dec. 2025 was $-2.86 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.37 Mil.

OSE Immunotherapeutics's quarterly Other Operating Expense increased from Dec. 2024 ($0.82 Mil) to Jun. 2025 ($2.48 Mil) but then declined from Jun. 2025 ($2.48 Mil) to Dec. 2025 ($-2.86 Mil).

OSE Immunotherapeutics's annual Other Operating Expense declined from Dec. 2023 ($8.78 Mil) to Dec. 2024 ($-7.83 Mil) but then increased from Dec. 2024 ($-7.83 Mil) to Dec. 2025 ($-0.34 Mil).

OSE Immunotherapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Other Operating Expense Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.91 10.34 8.78 -7.83 -0.34

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.12 -8.89 0.82 2.48 -2.86
ORPOF
51GF Score
OSE Immunotherapeutics SA ORPOF
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.37 Mil mean?
OSE Immunotherapeutics (ORPOF) has a Other Operating Expense of $-0.37 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on OSE Immunotherapeutics and its competitors.
Is OSE Immunotherapeutics' Other Operating Expense too high?
OSE Immunotherapeutics' current Other Operating Expense is $-0.37 Mil. Overall, OSE Immunotherapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Other Operating Expense compare to VRTX and REGN?
OSE Immunotherapeutics' Other Operating Expense of $-0.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current Other Operating Expense is $-0.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.33, compared to a current price of $4.43 — trading 33% above its estimated fair value. The current Other Operating Expense is $-0.37 Mil. OSE Immunotherapeutics' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Other Operating Expense is $-0.37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 33% above its estimated GF Value™ of $3.33. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for ORPOF:

  • Other Operating Expense: $-0.37 Mil
  • GF Value™: $3.33 vs. price of $4.43 (33% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
51GF Score

Get the complete analysis for ORPOF

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$3.33
GF Value